Skip to content
Inciteful Med

Tumor Surveillance: Protecting Your Child's Future

Last updated:

Children with Beckwith-Wiedemann syndrome require regular tumor surveillance to catch potential childhood cancers early. The standard protocol involves abdominal ultrasounds every 3 months until age 7, with specific blood or urine tests tailored to the child's molecular subtype.

Key Takeaways

  • • Early detection of BWS-related tumors through strict screening leads to excellent treatment outcomes and a very high chance of full recovery.
  • • The standard surveillance protocol requires abdominal ultrasounds every 3 months until the child reaches age 7.
  • • The need for routine AFP blood tests to check for liver tumors depends heavily on the child's specific molecular subtype.
  • • It is common and normal for parents to experience scan anxiety in the days leading up to these routine appointments.
  • • After age 7 or 8, the risk for these specific childhood cancers drops to the same level as children without BWS.

The most important part of caring for a child with Beckwith-Wiedemann Syndrome (BWS) is staying diligent with tumor surveillance. While the idea of your child being at risk for childhood cancers like Wilms tumor (kidney) or hepatoblastoma (liver) is terrifying, there is a very reassuring reality: early detection through this screening protocol leads to excellent treatment outcomes and a very high chance of a full recovery [1][2].

Why Screen Every 3 Months?

Doctors recommend screening every 3 months because childhood embryonal tumors can grow quickly [3][4]. By checking every 90 days, the medical team ensures they can catch any abnormal growth at an early, “low-stage” level [1]. At this stage, treatment is less intensive and highly effective [1].

The Standard Ultrasound Schedule

According to the 2018 International Consensus, the cornerstone of surveillance is:

  • Abdominal Ultrasounds: Performed every 3 months until age 7 for almost all children with BWS [5][6]. These painless scans check the kidneys, liver, and other abdominal organs [7].

Blood Tests: Tailored by Subtype

In the past, every child with BWS had blood drawn every 3 months to check alpha-fetoprotein (AFP), a marker for liver tumors [8]. However, modern medicine has proven that the risk for liver tumors depends heavily on your child’s specific molecular subtype [9][10]. Because blood draws are traumatic for young children, the 2018 guidelines recommend tailoring this test:

  • pUPD11 Subtype: This group has an increased risk for hepatoblastoma, so routine AFP blood tests every 3 months (until age 3 or 4) are highly recommended [8][11].
  • IC1-GoM & IC2-LoM Subtypes: The risk of hepatoblastoma in these groups is incredibly low (often under 1%) [8][12]. Therefore, routine AFP blood tests are generally not recommended by the 2018 Consensus to spare the child from unnecessary needle pokes and the extreme anxiety of false positives [8][13].
  • CDKN1C Mutations: These children have a unique risk for neuroblastoma (nerve tissue tumor) and require different screening, often involving urine tests rather than AFP [8][14].

Always discuss your child’s specific subtype with their oncologist to confirm the exact protocol.

Understanding “Scan Anxiety”

It is completely normal to feel a spike in fear, stress, and nausea in the days leading up to a scan—this is often called scan anxiety [15]. Balancing the burden of frequent medical visits with daily family life is a major undertaking [16].

Validation of these feelings is the first step in managing them. Remember that after your child reaches age 7 or 8, their risk for these specific tumors drops dramatically, often to the exact same level as any other child without BWS [7][17]. The screening phase is intense, but it is temporary, and it serves as a powerful, life-saving shield for your child.

Frequently Asked Questions

Why do children with BWS need an ultrasound every 3 months?
Embryonal tumors associated with BWS can grow very quickly. Screening every three months allows the medical team to catch any abnormal growth early, when treatment is less intensive and highly effective.
At what age can we stop BWS tumor surveillance ultrasounds?
Abdominal ultrasounds are generally recommended every three months until a child reaches age seven. After age seven or eight, the risk for these specific childhood tumors drops dramatically to the same level as the general population.
Does my child need routine AFP blood tests for BWS?
The need for alpha-fetoprotein (AFP) blood tests depends on your child's specific molecular subtype. While children with the pUPD11 subtype require routine AFP tests to monitor for hepatoblastoma, it is generally not recommended for those with IC1-GoM or IC2-LoM subtypes.
What kind of screening is needed for a CDKN1C mutation?
Children with a CDKN1C mutation have a unique risk for neuroblastoma, which is a nerve tissue tumor. They require a different screening approach that often relies on regular urine tests rather than AFP blood draws.

Questions for Your Doctor

  • • Which molecular subtype does my child have, and how does it specifically change our screening schedule?
  • • Based on their subtype (like IC1-GoM or IC2-LoM), are regular AFP blood tests medically necessary, or can we stick to just ultrasounds?
  • • At what age will the blood tests for hepatoblastoma (AFP) stop, and at what age will the ultrasounds for Wilms tumor stop?
  • • If my child has a CDKN1C mutation, should we be screening for neuroblastoma using a urine test?
  • • How quickly would we see a tumor grow, and is the every-3-month schedule sufficient to catch it while it is highly treatable?

Questions for You

  • • How am I coping with 'scan anxiety' before and after my child's appointments?
  • • Do I have a reliable system (like a calendar or app) for tracking my child's upcoming ultrasounds and blood tests?
  • • Have I connected with other BWS families who understand the unique pressure of chronic monitoring?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    The effectiveness of Wilms tumor screening in Beckwith-Wiedemann spectrum.

    Mussa A, Duffy KA, Carli D, et al.

    Journal of cancer research and clinical oncology 2019; (145(12)):3115-3123 doi:10.1007/s00432-019-03038-3.

    PMID: 31583434
  2. 2

    [Beckwith-Wiedemann syndrome with ganglioneuroblastoma: a case report].

    Tou JF, Feng CY, Xu B, Ye JJ

    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2025; (27(8)):1022-1026 doi:10.7499/j.issn.1008-8830.2502010.

    PMID: 40831174
  3. 3

    Decreased CDKN1C Expression in Congenital Alveolar Rhabdomyosarcoma Associated with Beckwith-Wiedemann Syndrome.

    Piersigilli F, Auriti C, Mondì V, et al.

    Indian journal of pediatrics 2016; (83(12-13)):1476-1478 doi:10.1007/s12098-016-2187-y.

    PMID: 27345568
  4. 4

    Genomic profiles of a hepatoblastoma from a patient with Beckwith-Wiedemann syndrome with uniparental disomy on chromosome 11p15 and germline mutation of APC and PALB2.

    Kim SY, Jung SH, Kim MS, et al.

    Oncotarget 2017; (8(54)):91950-91957 doi:10.18632/oncotarget.20515.

    PMID: 29190888
  5. 5

    [Tumor predisposition syndromes and nephroblastoma : Early diagnosis with imaging].

    Welter N, Furtwängler R, Schneider G, et al.

    Radiologie (Heidelberg, Germany) 2022; (62(12)):1033-1042 doi:10.1007/s00117-022-01056-w.

    PMID: 36008692
  6. 6

    Syndromic Wilms tumor: a review of predisposing conditions, surveillance and treatment.

    Liu EK, Suson KD

    Translational andrology and urology 2020; (9(5)):2370-2381 doi:10.21037/tau.2020.03.27.

    PMID: 33209710
  7. 7

    Diagnosis of Beckwith-Wiedemann syndrome in children presenting with Wilms tumor.

    MacFarland SP, Duffy KA, Bhatti TR, et al.

    Pediatric blood & cancer 2018; (65(10)):e27296 doi:10.1002/pbc.27296.

    PMID: 29932284
  8. 8

    Cancer Risk in Beckwith-Wiedemann Syndrome: A Systematic Review and Meta-Analysis Outlining a Novel (Epi)Genotype Specific Histotype Targeted Screening Protocol.

    Mussa A, Molinatto C, Baldassarre G, et al.

    The Journal of pediatrics 2016; (176()):142-149.e1.

    PMID: 27372391
  9. 9

    Molecular Basis of Beckwith-Wiedemann Syndrome Spectrum with Associated Tumors and Consequences for Clinical Practice.

    Eggermann T, Maher ER, Kratz CP, Prawitt D

    Cancers 2022; (14(13)) doi:10.3390/cancers14133083.

    PMID: 35804856
  10. 10

    Beckwith-Wiedemann spectrum (BWSp): an update on diagnosis, management, and follow-up from the scientific committee of the Italian BWSp association.

    Russo S, Milani D, Meossi C, et al.

    Italian journal of pediatrics 2025; (51(1)):287 doi:10.1186/s13052-025-02131-3.

    PMID: 41126215
  11. 11

    Cancer incidence and spectrum among children with genetically confirmed Beckwith-Wiedemann spectrum in Germany: a retrospective cohort study.

    Cöktü S, Spix C, Kaiser M, et al.

    British journal of cancer 2020; (123(4)):619-623 doi:10.1038/s41416-020-0911-x.

    PMID: 32451468
  12. 12

    Beckwith-Wiedemann syndrome: Clinical, histopathological and molecular study of two Tunisian patients and review of literature.

    Sassi H, Elaribi Y, Jilani H, et al.

    Molecular genetics & genomic medicine 2021; (9(10)):e1796 doi:10.1002/mgg3.1796.

    PMID: 34510813
  13. 13

    The utility of alpha-fetoprotein screening in Beckwith-Wiedemann syndrome.

    Duffy KA, Deardorff MA, Kalish JM

    American journal of medical genetics. Part A 2017; (173(3)):581-584 doi:10.1002/ajmg.a.38068.

    PMID: 28160403
  14. 14

    Expanded phenotype and cancer risk in patients with Beckwith-Wiedemann spectrum caused by CDKN1C variants.

    George AM, Viswanathan A, Best LG, et al.

    American journal of medical genetics. Part A 2024; (194(10)):e63777 doi:10.1002/ajmg.a.63777.

    PMID: 38822599
  15. 15

    Tumor screening in Beckwith-Wiedemann syndrome-To screen or not to screen?

    Kalish JM, Deardorff MA

    American journal of medical genetics. Part A 2016; (170(9)):2261-4 doi:10.1002/ajmg.a.37881.

    PMID: 27518916
  16. 16

    Depression and Anxiety in Pediatric Patients with Beckwith-Wiedemann Syndrome: A Pilot Study.

    D'Onofrio G, Mastromatteo A, Di Francesco A, et al.

    Children (Basel, Switzerland) 2024; (11(3)) doi:10.3390/children11030342.

    PMID: 38539377
  17. 17

    Comparison of Minimally Invasive Surfactant Therapy and Intubation-surfactant Administration-extubation in Premature Neonates with Respiratory Distress Syndrome.

    Al-Hinai AS, Al-Maawali A, Al-Kindi A, et al.

    Oman medical journal 2025; (40(1)):e712 doi:10.5001/omj.2025.44.

    PMID: 40630549

This page is for informational purposes only and does not replace professional medical advice. Always discuss your child's specific BWS molecular subtype and exact screening protocol with their pediatric oncologist.

Stay up to date

Get notified when new research about Beckwith-Wiedemann syndrome is published.

No spam. Unsubscribe anytime.